NeoTYPE® AML Prognostic Profile
Also known as: AML Prognostic Profile
Use
Molecular profiling with the NeoTYPE AML Prognostic Profile is appropriate for AML patients with intermediate-risk cytogenetic abnormalities, which is a heterogeneous group. This Profile can refine and improve risk stratification by confirming intermediate risk or reclassifying patients to more favorable or unfavorable risk categories. This change in risk classification may have therapeutic implications. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.
Special Instructions
FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing as a Client-Bill option. It is reported separately to support prompt therapy selection in newly diagnosed AML cases.
Limitations
Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies. Mercury fixatives (B5) should not be used. Note that the test is TNA-based and selecting Extract & Hold - TNA is advised if specimen hold service is desired.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Collection Instructions
Sodium heparin is acceptable.
Storage Instructions
Refrigerate specimen. Do not freeze.
Causes for Rejection
Mercury fixatives (B5). Highly acidic or prolonged decalcification processes.